tbuckley/cabot-search huggingface dataset:
ATNT-09BEVACIZUMAB FOR METASTATIC DURAL AND ORBITAL ESTHESIONEUROBLASTOMA
Authors: Richard Green, Emily Woyshner
Journal: Neuro-Oncology (2015)

Esthesioneuroblastoma is a malignant neuroectodermal tumor originating from the olfactory neuroepithelium. Bevacizumab is a specific inhibitor of the vascular endothelial growth factor ligand, preventing its interaction with receptors on endothelial cells. We report two cases of metastatic dural esthesioneuroblastoma that responded to bevacizumab. Patient 1, a 45 year-old man, had been treated initially for local disease with resection and radiation therapy (RT); for submandibular recurrence with radical neck dissection, RT, and cis-platinum plus etoposide; and subsequently for leptomeningeal disease with temozolomide plus sunitinib. He had an enlarging right orbital mass with progressive dural and leptomeningeal involvement. Patient 2, a 66 year-old woman, had been treated initially for local disease with craniotomy, RT, and cis-platinum; then for local recurrence with both regional and stereotactic RT. She developed enlarging orbital, dural and scalp masses. Both patients were treated with bevacizumab, 5 mg/kg every 2 weeks. Patient 1 achieved a partial response, with reduction in dural contrast enhancement, tumor cyst volumes, and perilesional edema, along with improvement in left leg weakness and right ptosis. His tumors progressed on imaging after 260 days of therapy. He died after 602 days of bevacizumab despite the addition of lomustine. Patient 2 achieved stable disease for 457 days but died of respiratory complications after developing a cerebrospinal fluid leak, without tumor progression. These patients with metastatic orbital and dural esthesioneuroblastoma achieved durable responses with bevacizumab therapy. Anti-angiogenic strategies may play a role in salvage therapy for this tumor.
Abstract 14788: Diagnostic Value of Fractional Flow Reserve Derived From Coronary Computed Tomographic Angiography by Hypertension or Smoking
Authors: Rine Nakanishi, Dong Li, Vivek Bhatia, Souma Sengputa, Suguru Matsumoto, Anas Alani, Bon-Kwon Koo, James K Min, Christopher Dailing, Matthew J Budoff
Journal: Circulation (2014)

Introduction:  A recent novel technique allows non-invasively to identify the lesion-specific ischemia by fractional flow reserve (FFR) derived from coronary computed tomographic angiography (CTA) (FFRCT) and calculated by computational combined models of anatomy, physiology, and fluid dynamics. However, its diagnostic value for subjects with or without hypertension or smoking associated with microvascular resistance has not been examined.   Hypothesis:  The aim of this study is to determine whether FFRCT predicts lesion-specific ischemia by invasive FFR among patients with or without hypertension or smoking.   Methods:  We identified 103 patients with suspected or known coronary artery disease enrolled from the DISCOVER-FLOW and DeFACTO prospective blinded studies who underwent invasive coronary angiography (ICA) with FFR and ≥64 slice coronary CTA. All patients had nitroglycerin before coronary CTA studies. FFRCT was derived from coronary CTA using the latest-generation computational fluid dynamic techniques (HeartFlow). Diagnostic value of FFRCT (≤0.80) and CTA stenosis (≥50% by the core labs) for predicting ischemia by invasive FFR (≤0.80) was assessed among patients with or without hypertension or smoking.   Results:  Out of 144 vessels, 52 vessels (36.1%) had lesion-specific ischemia by invasive FFR. On a per-vessel analysis, diagnostic accuracy of FFRCT was superior to that of CTA stenosis among patients with or without hypertension or smoking. The area under the curves (AUC) by receiver-operating characteristic curve analysis for FFRCT demonstrated significantly greater diagnostic performance for predicting ischemia compared to CTA stenosis regardless of the presence or absence of these risk factors (p   Conclusions:  Among patients with or without hypertension or smoking, FFRCT is a more reliable assessment for predicting lesion-specific ischemia by invasive FFR compared to CTA stenosis alone.
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
Authors: M Mossner, J-C Jann, D Nowak, U Platzbecker, A Giagounidis, K Götze, A Letsch, D Haase, K Shirneshan, F Braulke, R F Schlenk, T Haferlach, P Schafhausen, G Bug, M Lübbert, A Ganser, G Büsche, E Schuler, V Nowak, J Pressler, J Obländer, S Fey, N Müller, E Lauinger-Lörsch, G Metzgeroth, C Weiß, W-K Hofmann, U Germing, F Nolte
Journal: Leukemia (2016)
Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC).
Authors: M. A. Carducci, M. A. Eisenberger, S. R. Denmeade, S. F. Slovin, A. Jakobovits, M. Vincent, H. I. Scher, M. J. Morris
Journal: Journal of Clinical Oncology (2010)

4669 Background: AGS-1C4D4 is a fully human MAb directed to PSCA, a cell surface antigen expressed on tumor cells in the majority of patients with prostate, pancreatic and bladder cancers. AGS-1C4D4 is produced in CHO cells and has an identical sequence to that of the hybridoma-derived AGS-PSCA. Preclinical studies confirmed comparability to AGS-PSCA in tumor inhibition tissue cross reactivity and PK. Due to differences in glycosylation and ADCC in vitro, a limited AGS-1C4D4 phase I trial was undertaken to explore potential differences in safety and PK. Methods: Thirteen patients with metastatic CRPC were treated. AGS-1C4D4 was administered by IV infusion Q3W for 4 doses at 6, 12, 24, and 48 mg/kg. Primary endpoints were safety and PK. Secondary endpoints included immunogenicity and anti-tumor activity. Disease assessments were performed Q12W. Patients with stable disease (SD) were eligible to receive extended treatment at the same dose and schedule. Results: Nine of 13 patients completed 4 doses. Toxicities were primarily grade 1-2. No deaths or grade 3-4 treatment-related events, acute infusion-related toxicities, or anti AGS-1C4D4 antibodies have been reported. PK was linear. Similarly to AGS-PSCA, serum concentrations of AGS-1C4D4 declined biphasically and the final elimination Ph was characterized by a slow clearance rate (CL) and a long terminal T1/2. Median CL values for the 4 dose levels ranged from 0.10 to 0.14 mL/h-kg; and T1/2 was from 2.2 to 2.9 weeks. The target trough serum antibody concentration of 200 mg/ml, based on xenograft models, was reached in most of the higher dose patients with available PK data and was maintained with subsequent dosing. SD was reported in 5 (38%) patients and all these received extended dosing with total treatment duration of up to 36 weeks (median 24, range 18-36). No PSA responses were observed. Conclusions: AGS-1C4D4 was well tolerated. PK indicated slow clearance and long T1/2 similar to AGS-PSCA. Radiographic SD was noted in 38% of the patients. Despite preclinical differences in ADCC in vitro, this phase I study confirmed similar safety and PK to the hybridroma-derived AGS-PSCA. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Agensys Astellas Pharma Agensys
Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
Authors: P A Abraham, M G Macres
Journal: Journal of the American Society of Nephrology (1991)

This study analyzed blood pressure in hemodialysis patients treated with epoetin beta in multicenter trials. Antihypertensive drugs were prescribed as usual. Placebo-controlled trials compared epoetin (100 to 150 U/kg; N = 151) with placebo (N = 78) for 82 days. Hemoglobin (108 +/- 18 versus 75 +/- 14 g/L) (mean +/- SD) and diastolic blood pressure (84 +/- 14 versus 78 +/- 15 mm Hg) were greater (P less than 0.05) after epoetin. Clinically important increases in blood pressure (increases in diastolic blood pressure greater than or equal to 10 mm Hg and/or drug therapy) were more frequent with epoetin (58 versus 37%; P = 0.005). A dose-response trial compared epoetin, 25 U/kg (N = 42), 100 U/kg (N = 40), and 200 U/kg (N = 39) for 138 days. Increases in hemoglobin were dose dependent, but clinically important increases in blood pressure were not. In analyses of all patients treated with epoetin (N = 272), no baseline or final level of hemoglobin, or rate of hemoglobin rise, was a threshold for a rise in blood pressure. Patients requiring antihypertensive drugs or having uncontrolled hypertension (diastolic blood pressure greater than 90 mm Hg) at baseline had decreases in blood pressure (P less than 0.05) with antihypertensive therapy. Thus, compared with placebo, 21% of patients had clinically important increases in blood pressure during amelioration of anemia. The baseline or final levels of hemoglobin, the extent or rate of hemoglobin rise, or uncontrolled hypertension or antihypertensive drug use at baseline were not confirmed as risks. Antihypertensive drug therapy was important for blood pressure control.
Importance of timely monitoring of seasonal influenza vaccine effectiveness
Authors: Richard G Pebody, Kåre Mølbak
Journal: Eurosurveillance (2016)

Preview this article: Importance of timely monitoring of seasonal influenza vaccine effectiveness, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/16/eurosurv-21-30209-1-1.gif
Half of people seen at English hospitals after self harming do not receive mental health assessment
Authors: Susan Mayor
Journal: BMJ (2016)

Nearly half of people presenting to hospitals in England after self harming do not undergo specialist mental health assessment despite it being recommended by national guidelines, shows a large observational study that found an increasing rate of self harm in men over the past few years.1

Researchers analysed data on all people aged 15 and over who had presented after self harm to five general hospital emergency departments in Oxford, Manchester, and Derby in 2012, and they …
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With<i>CDK4</i>Inhibitor Palbociclib
Authors: Mark A. Dickson, Gary K. Schwartz, Mary Louise Keohan, Sandra P. D’Angelo, Mrinal M. Gounder, Ping Chi, Cristina R. Antonescu, Jonathan Landa, Li-Xuan Qin, Aimee M. Crago, Samuel Singer, Andrew Koff, William D. Tap
Journal: JAMA Oncology (2016)

More than 90% of well-differentiated or dedifferentiated liposarcomas (WD/DDLS) have CDK4 amplification. The selective CDK4 and CDK6 inhibitor palbociclib inhibits growth and induces senescence in liposarcoma cell lines and xenografts. Our prior phase 2 study demonstrated that treatment with palbociclib (200 mg daily for 14 days every 21 days) resulted in clinical benefit in WD/DDLS but moderate hematologic toxic effects. It is important to understand whether palbociclib at a new dose and schedule-125 mg daily for 21 days every 28 days-results in clinical benefit and manageable toxic effects.To determine the progression-free survival (PFS) at 12 weeks of patients with WD/DDLS treated with palbociclib (PD0332991).In this phase 2, nonrandomized, open-label clinical trial conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 years and older with advanced WD/DDLS and measurable disease by RECIST 1.1 were enrolled from December 2011 to January 2014 and followed to March 2015. Patients received oral palbociclib at 125 mg daily for 21 days in 28-day cycles.Primary end point was PFS. Secondary end points included response rate and toxic effects.Overall, 30 patients were enrolled in the initial cohort and 30 more in an expansion cohort. Median (range) age was 61.5 (35-87) years; 31 patients (52%) were male; median (range) Eastern Cooperative Oncology Group score was 0 (0-1). Progression-free survival at 12 weeks was 57.2% (2-sided 95% CI, 42.4%-68.8%), and the median PFS was 17.9 weeks (2-sided 95% CI, 11.9-24.0 weeks). There was 1 complete response. Toxic effects were primarily hematologic and included neutropenia (grade 3, n = 20 [33%]; grade 4, n = 2 [3%]) but no neutropenic fever.In patients with advanced WD/DDLS, treatment with palbociclib was associated with a favorable PFS and occasional tumor response. This dose and schedule appears active and may have less toxic effects than 200 mg for 14 days.clinicaltrials.gov Identifier: NCT01209598.
Androgens, brain, and behavior
Authors: D R Rubinow, P J Schmidt
Journal: American Journal of Psychiatry (1996)

This article defines androgens (and anabolic steroids), describes their mechanisms of action, and summarizes their behavioral effects and relevance in animals and humans.A MEDLINE-derived review of the literature on androgens and behavior was performed; pivotal earlier publications were also obtained and included in the review.In animals, the effects of androgens on brain structure and function are well-established and profound, with behavioral implications extending far beyond reproduction. Androgens play a prominent role in the organization or programming of brain circuits, which are subsequently activated by gonadal steroids. In humans, roles for androgens have been described, albeit inconsistently, in the regulation of sexuality, aggression, cognition, emotion, and personality. The relevance of androgens for psychiatry is further suggested by gender-related differences in pharmacokinetics/pharmacodynamics and in the prevalence, course, and treatment response characteristics of several psychiatric disorders. Direct psychoactive effects of exogenously administered androgens have been described for many years, most recently in reports of the psychotoxic effects of anabolic steroids.Data from both animals and humans suggest that the biological and behavioral responses to androgens are context-dependent.
Proton beam therapy for medulloblastoma – Author's reply
Authors: Torunn I Yock, Nancy J Tarbell, Beow Y Yeap, David H Ebb, Elizabeth Weyman, Bree R Eaton, Nicole A Sherry, Robin M Jones, Shannon M MacDonald, Margaret B Pulsifer, Beverly Lavally, Annah N Abrams, Mary S Huang, Karen J Marcus
Journal: The Lancet Oncology (2016)
Abstract P322: Goals for Cardiometabolic Risk Factors are Still Not Being Attained in the Long Term After Stroke or Transient Ischaemic Attack
Authors: Muideen T Olaiya, Dominique A Cadilhac, Joosup Kim, Mark R Nelson, Velandai K Srikanth, Christopher F Bladin, Richard P Gerraty, Sharyn M Fitzgerald, Thanh Phan, Judith Frayne, Amanda G Thrift
Journal: Circulation (2016)

Introduction: Clinical guidelines for patients with stroke or TIA have focused on modification of lifestyle and treatment to achieve cardometabolic risk factor goals. However, there is limited evidence on effective attainment of these goals in this high-risk population. Hypothesis: We hypothesised that a one-year intervention program will improve the attainment of cardiometabolic risk factor goals in community-dwelling survivors of stroke or TIA. Methods: Shared Team Approach between Nurses and Doctors For Improved Risk Factor Management (STANDFIRM) trial is an on-going prospective, randomised controlled trial of risk factor management in people with stroke or TIA. Patients hospitalised for stroke/TIA, and aged ≥18 years, were provided an intervention comprising an individualised, evidence-based secondary prevention program, including nurse education visits, and management plan with specialist oversight. The study outcome was attainment of blood pressure, blood cholesterol, blood sugar, body composition, kidney function goals, and smoking cessation at 12 months, based on guideline recommendations. We assessed whether lifestyle or other factors were associated with achieving an increased number of goals. Data collection comprised surveys, anthropometric and biochemical measurements. Differences in the proportion of patients meeting the set goals at baseline and 12 months were determined using McNemar’s chi-square test. The association between baseline factors and goal attainment was determined using multivariable linear regression. Results: Between January 2010 and November 2013, 233 patients (66% male, median age 69 years, 77% ischaemic stroke) were recruited into the intervention arm of the trial. Between baseline and 12 months, there was no difference in the proportion of patients achieving each of the set goals. Overall, only 14 patients (3%) achieved all six measured goals. A total of 90 patients (34%) met ≥4 goals, 89 (34%) met 3 goals, and 84 (32%) met ≤2 goals. In multivariable analyses, factors independently associated with achieving more goals included being female (OR 1.70, 95% CI 1.27, 2.20), having vocational or higher education (OR 1.37, 95% CI 1.05, 1.80), and lower salt intake at baseline (OR 0.98, 95% CI 0.97, 1.00). Conclusion: The 12-month intervention did not have an impact on the attainment of cardiometabolic goals in patients with stroke or TIA. With few individual factors identified, further investigation of system-level factors is warranted to ascertain factors that could facilitate improved risk factor management in patients with stroke or TIA.
Predicting Venous Thromboembolism in Pediatric Trauma Patients—Reply
Authors: Christopher R. Connelly, Amy Laird, Jennifer M. Watters
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Late reactions in food‐allergic children and adolescents after double‐blind, placebo‐controlled food challenges
Authors: J. Saleh‐Langenberg, B. M. J. Flokstra‐de Blok, N. AlAgla, B. J. Kollen, A. E. J. Dubois
Journal: Allergy (2016)

Abstract The time during which children are observed following a double‐blind, placebo‐controlled food challenge ( DBPCFC ) varies in clinical practice. There are little data on late reactions ( LR s) following DBPCFC s. Therefore, we determined the prevalence, severity and clinical characteristics of late reactions in food‐allergic children and adolescents after DBPCFC , and ascertained which factors are associated with, and may predict, LR s. Logistic regression analyses were performed to investigate which factors were associated with LR s and to develop the association and prediction models. A total of 1142 children underwent DBPCFC s (child–test combinations). Of these 1142 child–test combinations, 400 reported LR s following the DBPCFC . LR s in food‐allergic children after DBPCFC are poorly predictable and are generally not severe. All LR s, including those on the placebo day, are more frequently reported in younger children. Children who do not experience severe immediate reactions may be safely discharged home 2 h after a DBPCFC .
Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program.
Authors: Christophe Massard, Marianne Oulhen, Sylvestre Le Moulec, Yohann Loriot, Nathalie Auger, Philippe Beuzeboc, Laurence Albiges, Stephane Culine, Stephane Oudard, Christophe Hennequin, Philippe Vielh, Françoise Farace, Karim Fizazi
Journal: Journal of Clinical Oncology (2015)

165 Background: In order to optimize molecular screening in advanced prostate cancer patients, we implemented a prospective molecular triage trial PETRUS (NCT01786031), based on molecular characterization of fresh tumor biopsies and circulating tumor cells (CTCs) in patients with mCRPC. The primary objective was to investigate the feasibility of prospectively performing molecular profiling of CRPC patients. Methods: A tumor biopsy from a metastatic and tumor primary site, along with blood samples specimen were collected from patients, and both frozen and FFPE samples were obtained. CTCs were detected using two methods, CellSearch and filtration (ISET, isolation by Size of Epithelial Tumor cells) combined to four-color immunofluorescent staining. Results: From December 2012 and March 2014, 51 CRPC patients with metastases accessible for biospy were included in 5 centres in France. Tumor biospy were successful (≥ 50% tumor cells) in 36/51 pts (72%). CTCs with different phenotypes were detected by CellSearch and ISET combined to four-color immunofluorescent staining in 28 (51%) pts. FISH AR and ERG was successful in only 54% and 32% of metastasis biopsies and primitive tumors respectively, most likely due to the absence of tumor cells or overfixation. The ISET platform was able to detect CTCs clusters, CTCs expressing epithelial and vimentin markers. AR amplification and ERG rearrangement analyses showed high level of heterogeneity with evidence of multiple CRPC iCTC subpopulation. A high level of heterogeneity between CTCs, metastasis biopsies and primitive tumors was observed for ERG rearrangement and AR amplification status. Conclusions: Our results demonstrate that CTCs could be an alternative source for surrogate molecular marker assessment in mCRPC, but neither approach could truly reflect the extreme heterogeneity observed in CTCs from mCRPC. Our preliminary results suggest also the operational feasibility of metastatic tumor biopsy: high interest for patients, significant yield of tumor biopsies and ad hoc molecular analysis. Clinical trial information: NCT01786031.
Stupor, Hypercalcemia and Carcinoma of the Renal Pelvis
Authors: Hal H. Bourne, Richard E. Tremblay, Julian S. Ansell
Journal: New England Journal of Medicine (1964)

SINCE Albright1 suggested that some tumors "might be producing parathyroid hormone," hypercalcemia associated with malignant tumors without bony metastases has been recorded with increasing frequency.2 3 4 5 Transitional-cell carcinoma of the renal pelvis is here added to the list of neoplasms that hypercalcemia may accompany.Case ReportA 69-year-old oyster farmer entered the hospital in stupor. In 1918 he had received a shrapnel wound to the right kidney, and in 1930 a right-sided staghorn calculus had been demonstrated. During the year before admission progressive anorexia, nausea, vomiting, constipation, weight loss, episodic chills and fever, lassitude, confusion, inappropriate behavior and finally progressive somnolence . . .
Hypersplenism Due to Infection
Authors: James H. Jandl, Harry S. Jacob, Geneva A. Daland
Journal: New England Journal of Medicine (1961)

INFECTION often entails anemia. Usually, this is of mild or moderate severity, appears during prolonged illness and is principally the result of erythroid bone-marrow hypofunction.1 Occasionally, however, a hemolytic anemia develops in association with infection. At least three distinctive, although uncommon, hemolytic syndromes have been delineated: an acute, often lethal, intravascular hemolysis may occur during blood-stream invasion by organisms such as Clostridium welchii that produce hemolysins2; direct infection of red cells, as by the red-cell-adherent organism Bartonella bacilliformis,3 may cause red-cell trapping in the spleen and acute hemolytic anemia; and an acute or chronic hemolytic anemia may develop during . . .